Obagi Medical, a notable player in the field of physician-dispensed skincare, has released significant new clinical data regarding its hyaluronic acid injectables during the recent American Society for Dermatologic Surgery (ASDS) Annual Meeting. Taking place from November 13 to 16, 2025, in Chicago, Illinois, this event served as a platform for leading dermatology professionals to share advancements in skin treatment.
The pivotal study presented by Dr. Sue Ellen Cox focused on a comparison of two hyaluronic acid fillers aimed at midface augmentation. This research not only highlighted the efficacy of Obagi’s injectable products but also showcased them as a leading option for improving the appearance of nasolabial folds. The findings from this study earned a place among the top ten abstracts presented at the conference, underscoring its importance within the dermatological community.
Hyaluronic acid fillers have gained popularity for their ability to restore volume and enhance facial contours. The findings from the FDA study indicate that Obagi’s products not only delivered satisfactory aesthetic results but also contributed to patient comfort and safety during procedures. This aspect is particularly crucial in the competitive landscape of aesthetic medicine, where patient experiences can significantly influence treatment choices.
The data presented at the ASDS meeting aligns with Obagi Medical’s commitment to advancing skincare solutions that prioritize both efficacy and safety. The company, which operates under the umbrella of Waldencast plc, has consistently pushed the boundaries of innovation in the dermatological field. The presentation at ASDS reflects their ongoing dedication to evidence-based practices and the development of high-quality products for healthcare professionals.
As the aesthetic market continues to evolve, the importance of clinical data in guiding treatment options cannot be overstated. With the newly revealed findings, Obagi Medical reinforces its position as a trusted provider of effective skincare solutions. The enthusiastic response from the dermatology community highlights the potential for these injectables to become a preferred choice for both practitioners and patients.
Looking ahead, Obagi Medical plans to expand its research efforts and continue exploring the applications of hyaluronic acid across various skincare products. The positive reception at the ASDS Annual Meeting marks a significant milestone for the company, paving the way for further advancements in the field of aesthetic dermatology.
